NASDAQ:NLTX Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis $16.60 -1.03 (-5.84%) As of 01/17/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends About Neoleukin Therapeutics Stock (NASDAQ:NLTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neoleukin Therapeutics alerts:Sign Up Key Stats Today's Range$16.14▼$17.7550-Day Range$3.49▼$71.5352-Week Range$2.03▼$14.36Volume159,375 shsAverage Volume50,104 shsMarket Capitalization$156.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Read More… Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLTX Stock News HeadlinesHead to Head Comparison: Tonix Pharmaceuticals (NASDAQ:TNXP) & Neoleukin Therapeutics (NASDAQ:NLTX)January 17, 2025 | americanbankingnews.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you to accelerate your retirement during the first 100 days of his administration.January 21, 2025 | InvestorPlace (Ad)Neoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comSee More Headlines NLTX Stock Analysis - Frequently Asked Questions How have NLTX shares performed this year? Neoleukin Therapeutics' stock was trading at $22.86 at the beginning of the year. Since then, NLTX shares have decreased by 27.4% and is now trading at $16.60. View the best growth stocks for 2025 here. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) released its quarterly earnings results on Thursday, November, 4th. The company reported ($5.60) EPS for the quarter, meeting the consensus estimate of ($5.60). When did Neoleukin Therapeutics' stock split? Neoleukin Therapeutics's stock reverse split before market open on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of Neoleukin Therapeutics? Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neoleukin Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), General Electric (GE) and CrowdStrike (CRWD). Company Calendar Last Earnings11/04/2021Today1/21/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NLTX CUSIPN/A CIK1404644 Webwww.neoleukin.com Phone(866) 245-0312Fax778-331-4486Employees90Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.22% Return on Assets-30.91% Debt Debt-to-Equity RatioN/A Current Ratio15.33 Quick Ratio15.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.08 per share Price / Book1.50Miscellaneous Outstanding Shares9,398,000Free Float9,250,000Market Cap$156.01 million OptionableNo Data Beta1.11 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NLTX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.